BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...platform. In 2019, Takeda exclusively licensed rights to solid tumor CAR T therapies NIB-102 and NIB-103...
BioCentury | Apr 30, 2019
Distillery Therapeutics

The Parkinson's drug Comtam for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes In silico and mouse studies identified Comtan entacapone as an FTO inhibitor that could help treat obesity and diabetes. An in silico screen of FDA-approved drugs for FTO binding...
BioCentury | Dec 15, 2017
Financial News

Clover raises RMB62.8M in series A

On Dec. 14, Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by new investor Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using...
BioCentury | Dec 14, 2017
Financial News

Clover raises RMB62.8M in series A

Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target...
BioCentury | May 5, 2016
Distillery Therapeutics

Therapeutics: NLR family apoptosis inhibitory protein 1 (NAIP1); NAIP2; NAIP5

Infectious disease INDICATION: Gram-negative bacterial infection; sepsis Cell culture and mouse studies suggest inhibiting NAIP1 , NAIP2 or NAIP5 could help treat lethal Gram-negative bacterial infections and sepsis. In primary mouse macrophages infected with Burkholderia thailandensis,...
BioCentury | Sep 16, 2013
Product Development

Continental drift

Cancer company BeiGene Co. Ltd. was founded in Beijing in 2010 in part to access China's large and growing pool of scientific talent. When it came time to build an SAB with clinical development expertise,...
BioCentury | Feb 7, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HBV; HDV Solute carrier family 10 sodium/bile acid cotransporter family member 1 (SLC10A1) In vitro and cell culture studies suggest...
BioCentury | Oct 25, 2012
Strategy

China's new mAb institute

The launch of the Shanghai Institute for Advanced Immunochemical Studies marks China's first attempt to establish a center of antibody research on par with research centers in the U.S. and Europe. Although details are still...
BioCentury | Sep 3, 2012
Strategy

Back to School 2012: Science & austerity

We have entered an age of austerity that, given the fecklessness of the political classes, won't end any time soon. Against that backdrop, the global science community must decide how to succeed with less money....
BioCentury | Oct 17, 2011
Strategy

Jumpstart to the clinic

After spending a year building a discovery pipeline from scratch, BeiGene Ltd. last week in-licensed two compounds from Johnson & Johnson that move the Chinese biotech into Phase II. The first-in-class programs include a mAb...
Items per page:
1 - 10 of 31
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...platform. In 2019, Takeda exclusively licensed rights to solid tumor CAR T therapies NIB-102 and NIB-103...
BioCentury | Apr 30, 2019
Distillery Therapeutics

The Parkinson's drug Comtam for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes In silico and mouse studies identified Comtan entacapone as an FTO inhibitor that could help treat obesity and diabetes. An in silico screen of FDA-approved drugs for FTO binding...
BioCentury | Dec 15, 2017
Financial News

Clover raises RMB62.8M in series A

On Dec. 14, Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by new investor Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using...
BioCentury | Dec 14, 2017
Financial News

Clover raises RMB62.8M in series A

Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target...
BioCentury | May 5, 2016
Distillery Therapeutics

Therapeutics: NLR family apoptosis inhibitory protein 1 (NAIP1); NAIP2; NAIP5

Infectious disease INDICATION: Gram-negative bacterial infection; sepsis Cell culture and mouse studies suggest inhibiting NAIP1 , NAIP2 or NAIP5 could help treat lethal Gram-negative bacterial infections and sepsis. In primary mouse macrophages infected with Burkholderia thailandensis,...
BioCentury | Sep 16, 2013
Product Development

Continental drift

Cancer company BeiGene Co. Ltd. was founded in Beijing in 2010 in part to access China's large and growing pool of scientific talent. When it came time to build an SAB with clinical development expertise,...
BioCentury | Feb 7, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HBV; HDV Solute carrier family 10 sodium/bile acid cotransporter family member 1 (SLC10A1) In vitro and cell culture studies suggest...
BioCentury | Oct 25, 2012
Strategy

China's new mAb institute

The launch of the Shanghai Institute for Advanced Immunochemical Studies marks China's first attempt to establish a center of antibody research on par with research centers in the U.S. and Europe. Although details are still...
BioCentury | Sep 3, 2012
Strategy

Back to School 2012: Science & austerity

We have entered an age of austerity that, given the fecklessness of the political classes, won't end any time soon. Against that backdrop, the global science community must decide how to succeed with less money....
BioCentury | Oct 17, 2011
Strategy

Jumpstart to the clinic

After spending a year building a discovery pipeline from scratch, BeiGene Ltd. last week in-licensed two compounds from Johnson & Johnson that move the Chinese biotech into Phase II. The first-in-class programs include a mAb...
Items per page:
1 - 10 of 31